Skip to main content
TipRanks
Go Ultimate75% OFF

Polynovo (MFJ) AI Stock Analysis

0 Followers
DE:MFJ

Polynovo

(Frankfurt:MFJ)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Broad-based revenue and account growthStrong growth across the core product platform and continued hospital-account additions indicate expanding adoption rather than dependence on a single customer or market. Geographic gains and broader U.S. penetration should support a larger commercial base over the next several quarters.
Negative Factors
Margin and profitability volatilityAlthough PolyNovo is profitable, the decline in net margin and wide gross-margin variation show that earnings quality is not yet consistently established. Continued mix, cost, or production variability could limit operating leverage and make future profit growth less predictable.

Polynovo (MFJ) vs. iShares MSCI Germany ETF (EWG)

-30%-20%-10%0%10%20%30%DE:MFJ-15.83%EWG+9.20%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 445.77M
Dividend Yield
―
Average Volume (3M)
590
Price to Earnings (P/E)
83.5
Beta (1Y)
1.07
Revenue Growth
10.61%
EPS Growth
-43.36%
Country
Germany
Employees
301
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Polynovo Business Overview & Revenue Model

Company Description

PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix,...

Polynovo Earnings Call Summary

Earnings Call Date:Aug 25, 2026(Q4-2026)|% Change Since:-17.21%|Next Earnings Date:Mar 02, 2027
Earnings Call SentimentPositive

The call communicates strong commercial momentum across products (notably MTX), significant sales and adjusted EBITDA growth, positive cash generation and strategic investments (new facility, strengthened leadership, clinical evidence). Several manageable near-term headwinds were disclosed: FX volatility, one-off impacts from an R&D lab fire, lumpy large-burn case volumes affecting H2 U.S. growth, reimbursement turbulence for outpatient launches, and timing risks tied to PMA approval and facility transition. Overall the positives (robust growth rates, record months, strong cash flow, substantial MTX adoption and regulatory progress) materially outweigh the challenges, which are largely operational, timing or one-off in nature.

Positive Updates

Group Revenue Growth
NovoSorb product sales of $138.4M, up 16.7% YoY (21.3% in constant currency), with dollar sales increasing by $19.7M.

Negative Updates

Second-Half U.S. Growth Variability
H2 FY'26 saw fewer large burn cases presented (large burns are lumpy), contributing to a slower H2 U.S. trajectory despite broadening into other procedures; reliance on variable large-case volume remains a near-term volatility factor.

Company Guidance

The call guided that PolyNovo is entering FY'27 with strong momentum and clear priorities — advancing the PMA (submission planned this calendar year with FDA review ~12 months), sharing the RCT results, launching SynPath into U.S. outpatient, accelerating MTX, increasing innovation velocity and improving operating leverage — after FY'26 NovoSorb product sales of $138.4M (up 16.7% YoY; +21.3% constant currency), U.S. sales $102.1M (+15.6%/+21.1% cc), Rest of World $36.3M (+20.0%/+21.9% cc), MTX sales $12.6M (+89.6%) with MTX $12.2M in the U.S. (+92.7% cc) and MTX now in 6 markets; the U.S. business added ~200 hospital accounts to >880 total and MTX is used in >330 U.S. accounts, supported by 132 U.S. staff (106 sales), while group July sales set a record at >$13M and June was a U.S. record. Financially, adjusted EBITDA was $13.4M (+50.4% after significant items), free cash flow was $9.4M, cash from operations $23.1M, cash on hand $35.4M, FY gross margin 89.0% (H2 89.2%, July ~95%; new facility expected to modestly reduce margin by ~1–1.5% once ramped), CapEx during the year was $13.8M (including $12.4M for the new facility; $1.5M machinery outstanding), R&D guidance ~5% of sales next year, and regional performance highlights included Americas >AUD100M, Australia +33.9%, Ireland +38.3%, Hong Kong +49.9%, Turkey +79% and India +52.8%, with Rest of World now 26.2% of global sales.

Polynovo Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:MFJ against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AU:COHAU:COH68NeutralAUD 9.86B67.038.01%2.29%-0.90%-62.14%
AU:ARXAU:ARX61NeutralAUD 165.83M40.004.96%―19.23%―
AU:EYEAU:EYE57NeutralAUD 45.59M-10.53-28.79%―19.13%58.47%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:EBRAU:EBR39UnderperformAUD 131.05M-1.15-143.78%―1051.49%30.45%
AU:MX1AU:MX138UnderperformAUD 21.08M-1.96-188.06%―15.58%37.17%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:MFJAU:EYEAU:COHAU:MX1AU:ARXAU:EBRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:MFJ and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:MFJPolynovo Limited0.51-0.10-17.21%
AU:EYENova Eye Medical Ltd0.160.0323.08%
AU:COHCochlear Limited150.83-115.31-43.33%
AU:MX1Micro-X Ltd.0.03-0.06-68.89%
AU:ARXAroa Biosurgery Ltd0.48-0.17-26.15%
AU:EBREBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh0.15-0.85-84.52%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.